



iMetabolic
Biopharma Corporation

iMBP & FCS Foundation Join Forces

iMetabolic Biopharma Corporation (iMBP) and the FCS Foundation are pleased to announce that they are joining forces to create awareness about the devastating disease Familial Chylomicronemia Syndrome (FCS).

Who are iMBP and the FCS Foundation?

iMBP is an early stage biopharma company that is developing new therapeutics for the treatment of obesity related disease. Their developing lead molecule has demonstrated efficacy in human tissues that has the potential to treat FCS.

The FCS Foundation is a grass roots non-profit organization with the mission to establish a global support network to promote advocacy and education for patients and caregivers living with FCS. The FCS Foundation is the only foundation dedicated to patients suffering from Familial Chylomicronemia Syndrome.

What is FCS?

FCS is a genetic condition that causes a buildup of fats in the blood that can lead to potentially fatal attacks of pancreatitis and other severely debilitating symptoms. As FCS patients are unable to digest fats, and there are no FDA approved drugs, patients manage their disease by limiting fat intake to less than 20 grams per day.

- FCS is rare, but often misdiagnosed until later in life.
- There are no FDA approved drug treatments
- No standard of care currently exists for FCS patients.

"The FCS Foundation is thrilled to announce their partnership with iMetabolic Biopharma. Together, we hope to continue raising awareness for FCS and move toward improving quality of life for patients through advocacy and education"

- Lindsey Sutton - Co-president FCS Foundation

Follow us on:
[Facebook.com/iMBPCorp](https://www.facebook.com/iMBPCorp)
[Twitter.com/iMetabiopharma](https://twitter.com/iMetabiopharma)

Contact us:
info@imbiopharma.com



iMetabolic
Biopharma Corporation